FrancophonIA/ELRC3.0 huggingface dataset:
English: In the case of low to medium levels of maternally derived antibodies against PCV2 a single vaccination (2 ml) to pigs from an age of 3 weeks onwards is advised.
Estonian: PCV2 vastaste maternaalsete antikehade madala ja keskmise taseme korral on soovitav sigade ühekordne vaktsineerimine (2 ml) alates 3. elunädalast.
English: For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce mortality and weight loss associated with PCV2 infection occurring during the fattening period.
Estonian: Sigade aktiivseks immuniseerimiseks vähendamaks viiruse hulka veres ja lümfoidkoes ning vähendamaks nuumaperioodil PCV2 nakkusega seotud kaalulangust ja suremust.
English: Before using the vaccine, allow it to reach room temperature and shake well before use.
Estonian: Enne kasutamist lasta vaktsiinil soojeneda toatemperatuurini.
English: 346 mg light liquid paraffin.
Estonian: Kerge vedel parafiin 346 mg
English: Avoid multiple vial broaching.
Estonian: Vältida viaalide korduvat avamist.
English: Excipients.
Estonian: Süstevesi.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/08/091/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/08/091/001
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJAD JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV TOOTJA
English: PCV2 ORF2 subunit antigen: ≥ 4.5 log2 ELISA units.
Estonian: PCV2 ORF2 alaühiku antigeeni: ≥ 4,5 log2 ELISA ühikut
English: Cardboard boxes with either 1 or 10 PET vials of 20, 50, 100, 200 or 500 ml.
Estonian: Kartongist karbis on 1 või 10 PET viaali, mis sisaldavad 20, 50, 100, 200 või 500 ml.
English: If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.
Estonian: Kui olete juhuslikult endale seda veterinaarravimit süstinud,võtta kaasa pakendi infoleht ja pöörduda kiiresti arsti poole, isegi kui süstitud kogus oli väga väike.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/08/091/001-010
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/08/091/001-010
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Per 2 ml dose:
Estonian: TOIMEAINE(TE) KOGUS 2 ml doosis:
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard boxes {20, 50, 100, 200 and 500 ml}
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Kartongist karbid {20, 50, 100, 200 and 500 ml}
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vials {20 and 50 ml}
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: SPECIAL WARNING(S), IF NECESSARY Accidental self-injection is dangerous.
Estonian: Juhuslik ravimi endale süstimine on ohtlik.
English: STATEMENT OF ACTIVE AND OTHER SUBSTANCES One dose of 2 ml contains:
Estonian: TOIMEAINE(TE) JA ABIAINETE SISALDUS Üks doos (2 ml) sisaldab:
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection
Estonian: VETERINAARRAVIMI NIMETUS Porcilis PCV, süsteemulsioon
English: Porcine circovirus type 2 ORF2 subunit antigen: ≥ 4.5 log2 ELISA units.
Estonian: Sigade tsirkoviiruse tüüp 2 ORF2 alaühiku antigeeni: ≥ 4,5 log2 ELISA ühikut
English: Porcine circovirus type 2 ORF2 subunit antigen: at least 4.5 log2 ELISA units (as determined in the in vivo potency test in chickens)
Estonian: Sigade tsirkoviiruse tüüp 2 ORF2 alaühiku antigeeni: vähemalt 4,5 log2 ELISA ühikut (nagu on kindlaks määratud kanade in vivo potentsustestis).
English: A transient increase in body temperature, normally not exceeding 1 °C, was very commonly observed until 2 days after vaccination.
Estonian: Kahe päeva jooksul pärast vaktsineerimist täheldati sageli mööduvat kehatemperatuuri tõusu (tavaliselt kuni 1 °C).
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection for pigs
Estonian: VETERINAARRAVIMI NIMETUS Porcilis PCV, süsteemulsioon sigadele.
English: Porcine circovirus type 2 ORF2 subunit antigen: at least 4.5 log2 ELISA units* * Antibody titre obtained according to the in vivo potency test in chickens.
Estonian: Sigade tsirkoviiruse tüüp 2 ORF2 alaühiku antigeeni: vähemalt 4,5 log2 ELISA ühikut* *Antikehade tiiter vastavalt kanade in vivo potentsustesti tulemusele Adjuvandid:
English: EXPIRY DATE EXP {month/year} Once broached, use within 8 hours.
Estonian: Pärast esmast avamist kasutada kuni 8 tunni jooksul.
English: PACKAGE LEAFLET FOR: Porcilis PCV emulsion for injection for pigs
Estonian: PAKENDI INFOLEHT Porcilis PCV, süsteemulsioon sigadele
English: 25 mg dl-α-tocopheryl acetate
Estonian: Dl-α-tokoferüülatsetaat 25 mg
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vials {100, 200 and 500 ml}
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Viaalid {100, 200, 500 ml}
English: PHARMACEUTICAL FORM Emulsion for injection
Estonian: MANUSTAMISVIIS(ID)
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE C. STATEMENT OF THE MRLs
Estonian: BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV TOOTJA
English: EMEA-number Invented Name Strength Pharmaceutical Form
Estonian: Tugevus Ravimivorm Loomaliigid Manustamisviis Pakend
English: Nplate romiplostim
Estonian: Nplate romiplostiim
English: What measures are being taken to ensure the safe and effective use of Nplate?
Estonian: Mis meetmed võetakse, et tagada Nplate ohutu ja efektiivne kasutamine?
English: Other information about Nplate
Estonian: Muu teave Nplate kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nplate on 4 February 2009.
Estonian: Euroopa Komisjon andis Nplate müügiloa, mis kehtib kogu Euroopa Liidus, 4. veebruaril 2009.
English: Nplate is used when treatment with medicines such as corticosteroids or immunoglobulins has not worked.
Estonian: Nplatet kasutatakse, kui ravi selliste ravimitega nagu kortikosteroidid või immunoglobuliinid ei ole toiminud.
English: The European Medicines Agency decided that Nplate's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Nplate kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What is Nplate and what is it used for?
Estonian: Mis on Nplate ja milleks seda kasutatakse?
English: It is given once a week as an injection under the skin.
Estonian: Seda manustatakse üks kord nädalas nahaaluse süstina.
English: Therefore, in patients with intact spleens, the possibility of removing the spleen should be evaluated periodically.
Estonian: Seega peab põrnaga patsientidel korrapäraselt kaaluma põrna eemaldamise võimalust.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Nplate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Nplate kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: What are the risks associated with Nplate?
Estonian: Mis riskid Nplatega kaasnevad?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nplate have also been included in the summary of product characteristics and the package leaflet.
Estonian: Nplate ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Why is Nplate approved?
Estonian: Miks Nplate heaks kiideti?
English: The full EPAR for Nplate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Nplate kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Nplate contains the active substance romiplostim.
Estonian: Nplate sisaldab toimeainena romiplostiimi.
English: This is a summary of the European public assessment report (EPAR) for Nplate.
Estonian: See on ravimi Nplate Euroopa avaliku hindamisaruande kokkuvõte.
English: Two main studies in adults and a third one in children found Nplate effective for the treatment of longstanding ITP.
Estonian: Kahes täiskasvanute põhiuuringus ja kolmandas laste uuringus leiti, et Nplate on pikaajalise ITP ravis efektiivne.
English: Because the number of patients with ITP is low, the disease is considered ‘rare', and Nplate was designated an ‘orphan medicine' (a medicine used in rare diseases) on 27 May 2005.
Estonian: Et ITPga patsientide arv on väike ja see haigus esineb harva, nimetati Nplate 27. mail 2005 harvikravimiks.
English: All studies compared Nplate with placebo (a dummy treatment).
Estonian: Kõikides uuringutes võrreldi Nplatet platseeboga (näiv ravim).
English: The improvement in platelet count was long-lasting and clinically relevant in both groups, although the treatment only manages symptoms and is not a cure.
Estonian: Trombotsüütide arvu suurenemine oli mõlemas rühmas pikaajaline ja kliiniliselt oluline vaatamata sellele, et ravi leevendab ainult sümptomeid ega ravi haiguse tekkepõhjust.
English: Long-term studies involving over 1,000 patients, some treated for longer than 5 years, confirmed that Nplate remained effective both in patients whose spleen had been removed and those who had their spleen.
Estonian: Üle 1000 patsiendiga pikaajalistes uuringutes, milles teatud patsiente oli ravitud üle 5 aasta, kinnitati, et Nplate efektiivsus püsib nii patsientidel, kellel on põrn eemaldatud, kui ka põrnaga patsientidel.
English: It is not intended to provide practical advice on how to use Nplate.
Estonian: Hindamisaruandes ei anta Nplate kasutamise praktilisi nõuandeid.
English: Doctors can also receive a home administration training pack, which includes materials on training patients who will inject themselves with Nplate, and materials for patients on how to prepare the medicine for injection.
Estonian: Arstidele võidakse anda ka koduse manustamise väljaõppekomplekt, mis sisaldab teavet, kuidas õpetada patsiente ise Nplatet süstima, ja juhiseid patsientidele, kuidas ravimit süstimiseks ette valmistada.
English: The most common side effects in children include infections of the nose and throat, runny nose, cough, fever, mouth and throat pain, abdominal (belly) pain, diarrhoea, rash and bruising.
Estonian: Kõige sagedamad kõrvalnähud lastel on nina- ja neeluinfektsioonid, ninavoolus, köha, palavik, suu- ja kurguvalu, kõhuvalu, kõhulahtisus, lööve ja nahaalused verevalumid.
English: Nplate must not be used in people who are hypersensitive (allergic) to romiplostim, any of the other ingredients, or proteins produced by Escherichia coli (a bacterium).
Estonian: Nplatet ei tohi kasutada patsiendid, kes on romiplostiimi või selle ravimi mis tahes muu koostisaine või bakteri Escherichia coli toodetavate valkude suhtes ülitundlikud (allergilised).
English: The first study involved 63 patients whose disease was not controlled despite removal of their spleen.
Estonian: Esimeses uuringus osales 63 patsienti, kelle haigus ei allunud ravile vaatamata põrna eemaldamisele.
English: The most common side effects with Nplate in adults (seen in more than 1 patient in 10) include headache, infections of the nose and throat and allergic (hypersensitivity) reactions such as rash, itching and rapid swelling under the skin.
Estonian: Nplate kõige sagedamad kõrvalnähud täiskasvanutel (võivad esineda enam kui 1 patsiendil 10st) on peavalu, nina- ja neeluinfektsioonid ning allergilised (ülitundlikkuse) reaktsioonid, nagu lööve, sügelus ja kiire nahaalune turse.
English: By mimicking the action of thrombopoietin, romiplostim stimulates the production of platelets, thereby increasing blood platelet counts and reducing the risk of bleeding.
Estonian: Trombopoetiini toimet imiteerides stimuleerib romiplostiim trombotsüütide teket, suurendades nii trombotsüütide sisaldust veres ja vähendades veritsusriski.
English: Adults whose platelet levels are stable may inject the medicine themselves after they have been properly trained.
Estonian: Stabiilse trombotsüütide sisaldusega täiskasvanud patsiendid võivad pärast asjakohase väljaõppe saamist ravimit ka ise süstida.
English: The company that markets Nplate will provide doctors a ‘dosing calculator' to help them calculate the sometimes very small volumes of Nplate that need to be injected.
Estonian: Nplate tootja annab arstidele annustamiskalkulaatori, millega saab arvutada süstitava Nplate koguse, mis mõnikord on väga väike.
English: The study in children involved 62 patients aged 1 to less than 18 years whose ITP had been treated previously (including some whose spleen had been removed).
Estonian: Laste uuringus osales 62 patsienti vanuses 1 kuni <18 eluaastat, kelle ITP-d oli varem ravitud (sh mõned patsiendid, kelle põrn oli eemaldatud).
English: A platelet count below 30 million per millilitre puts patients at risk of bleeding while the normal count is 150 to 400 million per millilitre.
Estonian: Patsiendi veritsusrisk suureneb, kui trombotsüütide sisaldus on alla 30 miljoni milliliitri kohta, kusjuures trombotsüütide normaalne sisaldus on 150 kuni 400 miljonit milliliitri kohta.
English: For the full list of side effects reported with Nplate, see the package leaflet.
Estonian: Nplate kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For practical information about using Nplate, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Nplate kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The second study involved 62 patients whose ITP had been treated previously (but who did not have their spleen removed).
Estonian: Teises uuringus osales 62 patsienti, kelle ITP-d oli varem ravitud (kuid kelle põrna ei olnud eemaldatud).
English: For more information about treatment with Nplate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Nplatega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients with ITP have low platelet counts and are at risk of bleeding.
Estonian: ITPga patsientidel on trombotsüütide vähesus, mistõttu neil on veritsusrisk.
English: What benefits of Nplate have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Nplate kasulikkus?
English: Romiplostim has been designed to attach to and stimulate the same targets (receptors) as thrombopoietin.
Estonian: Romiplostiim on välja töötatud seonduma samade retseptoritega nagu trombopoetiin ja neid stimuleerima.
English: How does Nplate work?
Estonian: Kuidas Nplate toimib?
English: The starting dose depends on the patient's weight, and is then adjusted to maintain platelet counts at the target levels.
Estonian: Algannus sõltub patsiendi kehakaalust ja annust kohandatakse trombotsüütide sisalduse sihtväärtuse säilitamiseks.
English: Patients were treated for 24 weeks and the main measure of effectiveness was the increase in platelet count above a threshold of 50 million platelets per millilitre of blood during at least 6 of the last 8 weeks of treatment.
Estonian: Efektiivsus põhinäitaja oli trombotsüütide arvu suurenemine üle piirväärtuse - 50 miljonit trombotsüüti 1 ml vere kohta - vähemalt 6 nädala jooksul viimasest 8 ravinädalast.
English: Nplate can be used in patients whose spleen has been removed to control the disease and in those who still have a spleen.
Estonian: Nplatet võib kasutada nii patsientidel, kellel on haiguse ohjamiseks eemaldatud põrn, kui ka põrnaga patsientidel.
English: How is Nplate used?
Estonian: Kuidas Nplatet kasutatakse?
English: The Agency noted that Nplate was effective in patients who had had their spleen removed, as well as in patients who had not had their spleen removed.
Estonian: Amet märkis, et Nplate on efektiivne nii eemaldatud põrnaga kui ka eemaldamata põrnaga patsientidel.
English: Treatment should be stopped if the platelet count does not rise enough to reduce the risk of bleeding after 4 weeks of treatment with the maximum dose of Nplate.
Estonian: Kui 4-nädalase ravi järel Nplate maksimaalse annusega ei ole trombotsüütide arv veritsusriski piisavaks vähendamiseks suurenenud, tuleb ravi lõpetada.
English: Nplate can only be obtained with a prescription and treatment with it should be supervised by a doctor who has experience in treating blood disorders.
Estonian: Ravi peab toimuma verehaiguste ravis kogenud arsti järelevalve all.
English: The spleen, an organ behind the stomach, is involved in the removal of platelets from the blood.
Estonian: Mao taga paiknev organ põrn osaleb trombotsüütide eemaldamisel verest.
English: In the body, a hormone called ‘thrombopoietin' normally stimulates the production of platelets in the bone marrow.
Estonian: Normaalsetes tingimustes stimuleerib organismis hormoon trombopoetiin trombotsüütide teket luuüdis.
English: Platelet count rose above the threshold in 61% of patients who received Nplate (25 out of 41) compared with 5% receiving placebo (1 out of 21).
Estonian: Patsiente, kelle trombotsüütide arv ületas piirväärtuse, oli 61% Nplate rühmas (25 patsienti 41st) ning 5% platseeborühmas (1 patsient 21st).
English: Platelet count rose above the threshold in 52% of patients who received Nplate (22 out of 42) compared with 10% receiving placebo (2 out of
Estonian: Patsiente, kelle trombotsüütide arv ületas piirväärtuse, oli 52% Nplate rühmas (22 patsienti 42st) ja 10% platseeborühmas (2 patsienti 20st).
English: Platelet count rose above the threshold in 38% of patients who received Nplate (16 out of 42) compared with none of the 21 patients receiving placebo.
Estonian: Patsiente, kelle trombotsüütide arv ületas piirväärtuse, oli 38% Nplate rühmas (16 patsienti 42st), aga 0 platseeborühmas (kus oli 21 patsienti).
English: Nplate is a powder that is made up into a solution for injection.
Estonian: Nplate on süstelahuse pulber.
English: Nplate is used in patients from 1 year of age with long-term immune thrombocytopenic purpura (ITP), a disease in which the patient's immune system destroys platelets (components in the blood that help it to clot).
Estonian: Nplatet kasutatakse pikaajalise immuuntrombotsütopeenilise purpuriga (ITP) patsientide raviks alates 1. eluaastast.
English: The active substance in Nplate, romiplostim, stimulates the production of platelets.
Estonian: Nplate toimeaine romiplostiim stimuleerib trombotsüütide teket.
English: Tegsedi (inotersen)
Estonian: Tegsedi (inoterseen)
English: What measures are being taken to ensure the safe and effective use of Tegsedi?
Estonian: Mis meetmed võetakse, et tagada Tegsedi ohutu ja efektiivne kasutamine?
English: What is Tegsedi and what is it used for?
Estonian: Mis on Tegsedi ja milleks seda kasutatakse?
English: The European Medicines Agency therefore decided that Tegsedi's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Tegsedi kasulikkus on suurem kui sellega kaasnevad riskid ja lubati ravimi kasutamine ELis.
English: As for all medicines, data on the use of Tegsedi are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Tegsedi kasutamise kohta pidevat järelevalvet.
English: The main measures of effectiveness were the changes in the patients' nerve damage and quality of life, as measured using standard scales called ‘mNIS+7' and ‘Norfolk QoL-DN' respectively.
Estonian: Efektiivsuse põhinäitajad olid muutused patsiendi närvikahjustuses ja elukvaliteedis, mõõdetuna vastavatel standardskaaladel mNIS+7 ja Norfolk QoL-DN.
English: Further information on Tegsedi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Tegsedi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Tegsedi must not be used by patients with low platelet counts (less than 100x109/l), and by patients with severe kidney or liver problems.
Estonian: Tegsedit ei tohi kasutada vereliistakute väikese sisaldusega (vähem kui 100 x 109/l) ega raskete neeru- või maksaprobleemidega patsiendid.
English: This reduces production of transthyretin, thereby reducing the formation of amyloids and relieving the symptoms of hATTR amyloidosis.
Estonian: Nii väheneb transtüretiini tootmine, vähendades amüloidi moodustumist ja leevendades hATTRamüloidoosi sümptomeid.
English: In light of the unmet medical need, the safety profile of Tegsedi was considered acceptable and the risks to be manageable with specific monitoring, dose reduction and stopping rules.
Estonian: Arvestades täitmata ravivajadust, peeti Tegsedi ohutusprofiili aktsepteeritavaks ja riske spetsiifilise jälgimise, annuse vähendamise ja ravi peatamise reeglite kaudu käsitletavaiks.
English: For more information about using Tegsedi, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Tegsedi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The recommended dose is one injection once a week, given under the skin in the belly, upper thigh or upper arm.
Estonian: Soovitatav annus on üks süste üks kord nädalas, manustatuna kõhu, reie ülaosa või õlavarre naha alla.
English: The most common side effects with Tegsedi (which may affect more than 1 in 10 people) are reactions at the site of injection, nausea (feeling sick), low level of red blood cells, headache, fever, peripheral oedema (swelling, especially of the ankles and feet), chills, vomiting and low blood platelet counts which can lead to bleeding and bruising.
Estonian: Tegsedi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on süstekoha reaktsioonid, iiveldus, punavereliblede sisalduse vähenemine, peavalu, palavik, perifeersed tursed (paistetus, eriti hüppeliigestel ja labajalgadel), külmavärinad, oksendamine ning veritsusi ja verevalumeid põhjustada võiv vereliistakute väike sisaldus.
English: The medicine is available as a solution for injection under the skin in pre-filled syringes (284 mg).
Estonian: Ravimit turustatakse eeltäidetud süstaldes (284 mg) nahaaluse süstelahusena.
English: Side effects reported with Tegsedi are carefully evaluated and any necessary action taken to protect patients.
Estonian: Tegsedi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Tegsedi is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient is able to walk unaided, and stage 2, when the patient can still walk but needs help).
Estonian: Tegsedit kasutatakse täiskasvanud patsientidel, kellel on närvikahjustuse kaks esimest staadiumi (1. staadium: patsient on võimeline abita kõndima; 2. staadium: patsient on võimeline kõndima, kuid vajab abi).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tegsedi have also been included in the summary of product characteristics and the package leaflet.
Estonian: Tegsedi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ka ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: hATTR is rare, and Tegsedi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 26 March 2014.
Estonian: HATTR esineb harva ja Tegsedi nimetati 26. märtsil 2014 harvikravimiks.
English: How is Tegsedi used?
Estonian: Kuidas Tegsedit kasutatakse?
English: The active substance in Tegsedi, inotersen, is an ‘antisense oligonucleotide', a very short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin.
Estonian: Tegsedi toimeaine inoterseen on antisenss-oligonukleotiid - väga lühike sünteesitud geenimaterjal, mis on välja töötatud seonduma transtüretiini tootmise eest vastutava raku geeniga ja seda blokeerima.